We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Amoxicillin/clavulanic acid-warfarin drug interaction: a randomized controlled trial.
- Authors
Qian Zhang; Simoneau, Guy; Verstuyft, Celine; Drouet, Ludovic; Bal dit Sollier, Claire; Alvarez, Jean-Claude; Rizzo-Padoin, Nathalie; Bergmann, Jean Francois; Becquemont, Laurent; Mouly, Stéphane
- Abstract
• Increased INR was previously observed in patients treated with warfarin and amoxicillin/clavulanic acid (amoxiclav) combination. To date, no prospective study has yet evaluated the effect of amoxiclav on INR in patients on warfarin therapy and consequently, there are no clear-cut conclusions or clear recommendations for clinicians. • We provided the first systematic prospective evaluation of the interaction between amoxiclav and warfarin and found that amoxiclav did not modify INR in patients treated with stable warfarin therapy in the absence of any infectious or inflammatory syndrome, suggesting that the previously observed INR increase in these patients may not be attributable to a drug-drug interaction. To investigate whether an interaction exists between amoxicillin/clavulanic acid (amoxiclav) and warfarin in patients treated with stable oral anticoagulant therapy. In a double-blind, cross-over, placebo-controlled study, 12 patients on stable warfarin therapy, received a 7 day amoxiclav regimen or placebo. The mean maximum increase in INR observed was 0.22 ± 0.3 with amoxiclav vs. 0.24 ± 0.6 with placebo ( P= 0.94). The day 7-day 1 factor II, R(-) and S(-) warfarin plasma concentrations were similar during the amoxiclav and placebo study periods ( P= 0.81, P= 0.45, P= 0.75, respectively). Amoxiclav did not modify anticoagulation in patients treated with stable warfarin therapy and without infection.
- Publication
British Journal of Clinical Pharmacology, 2011, Vol 71, Issue 2, p232
- ISSN
0306-5251
- Publication type
Academic Journal
- DOI
10.1111/j.1365-2125.2010.03824.x